ATE326014T1 - Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma - Google Patents
Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasmaInfo
- Publication number
- ATE326014T1 ATE326014T1 AT99962732T AT99962732T ATE326014T1 AT E326014 T1 ATE326014 T1 AT E326014T1 AT 99962732 T AT99962732 T AT 99962732T AT 99962732 T AT99962732 T AT 99962732T AT E326014 T1 ATE326014 T1 AT E326014T1
- Authority
- AT
- Austria
- Prior art keywords
- ldl
- lipoprotein
- vldl
- compound
- plasma cholesterol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 4
- 108090001030 Lipoproteins Proteins 0.000 abstract 4
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000000853 LDL receptors Human genes 0.000 abstract 2
- 108010001831 LDL receptors Proteins 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10764498P | 1998-11-09 | 1998-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE326014T1 true ATE326014T1 (de) | 2006-06-15 |
Family
ID=22317677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99962732T ATE326014T1 (de) | 1998-11-09 | 1999-11-09 | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1137948B1 (de) |
| JP (1) | JP2002529740A (de) |
| CN (1) | CN1332849A (de) |
| AT (1) | ATE326014T1 (de) |
| AU (1) | AU1911200A (de) |
| CA (1) | CA2350316A1 (de) |
| DE (1) | DE69931279T2 (de) |
| IL (2) | IL143057A0 (de) |
| MX (1) | MXPA01004683A (de) |
| WO (1) | WO2000028332A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998051662A2 (en) * | 1997-05-14 | 1998-11-19 | Atherogenics, Inc. | Compounds and methods for the inhibition of the expression of vcam-1 |
| US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
| US6852878B2 (en) | 1998-05-14 | 2005-02-08 | Atherogenics, Inc. | Thioketals and thioethers for inhibiting the expression of VCAM-1 |
| CO5170498A1 (es) * | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
| US7012159B1 (en) | 1999-10-04 | 2006-03-14 | Nippon Soda Co., Ltd. | Phenolic compounds and recording materials containing the same |
| EP1289944A2 (de) * | 2000-03-21 | 2003-03-12 | Atherogenics, Inc. | Thioketale und thioether zur hemmung der expression von vcam-1 |
| AU2001253401B2 (en) * | 2000-04-11 | 2006-12-07 | Atherogenics, Inc | Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality |
| EP1392714B1 (de) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroide als agonisten für fxr |
| ITMI20020597A1 (it) * | 2002-03-22 | 2003-09-22 | Nicox Sa | Derivati del probucolo |
| US7294737B2 (en) | 2004-04-20 | 2007-11-13 | Atherogenics, Inc. | Process of preparing esters and ethers of probucol and derivatives thereof |
| US8252840B2 (en) | 2007-03-26 | 2012-08-28 | Salutria Pharmaceuticals Llc | Methods of derivatives of probucol for the treatment of type II diabetes |
| US8048880B2 (en) | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| JP2012530900A (ja) * | 2009-06-17 | 2012-12-06 | メイン スタンダーズ カンパニー リミテッド ライアビリティ カンパニー | リポタンパク質特異的アポリポタンパク質を測定する方法 |
| CN114085283A (zh) * | 2015-05-19 | 2022-02-25 | 拉·约拉过敏反应及免疫医学研究所 | 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途 |
| CN109789217A (zh) * | 2016-09-01 | 2019-05-21 | 凯文·乔恩·威廉姆斯 | 用于降低脂蛋白颗粒对动脉壁酶引起的致动脉粥样硬化性聚集的敏感度的方法和试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US5155250A (en) * | 1990-07-05 | 1992-10-13 | Merrell Dow Pharmaceuticals Inc. | 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents |
| AU681731B2 (en) * | 1993-12-10 | 1997-09-04 | Aventis Inc. | Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols |
| US5608095A (en) * | 1996-04-30 | 1997-03-04 | Hoechst Marion Roussel, Inc. | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
| CH691957A5 (de) * | 1996-09-03 | 2001-12-14 | Urs Tschudin | Schleifmaschine. |
-
1999
- 1999-11-09 MX MXPA01004683A patent/MXPA01004683A/es active IP Right Grant
- 1999-11-09 AT AT99962732T patent/ATE326014T1/de not_active IP Right Cessation
- 1999-11-09 CA CA002350316A patent/CA2350316A1/en not_active Abandoned
- 1999-11-09 WO PCT/US1999/026519 patent/WO2000028332A1/en not_active Ceased
- 1999-11-09 DE DE69931279T patent/DE69931279T2/de not_active Expired - Lifetime
- 1999-11-09 IL IL14305799A patent/IL143057A0/xx unknown
- 1999-11-09 AU AU19112/00A patent/AU1911200A/en not_active Abandoned
- 1999-11-09 CN CN99815245A patent/CN1332849A/zh active Pending
- 1999-11-09 EP EP99962732A patent/EP1137948B1/de not_active Expired - Lifetime
- 1999-11-09 JP JP2000581459A patent/JP2002529740A/ja active Pending
-
2001
- 2001-05-09 IL IL143057A patent/IL143057A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1137948A1 (de) | 2001-10-04 |
| DE69931279D1 (de) | 2006-06-14 |
| CN1332849A (zh) | 2002-01-23 |
| IL143057A (en) | 2010-04-15 |
| EP1137948B1 (de) | 2006-05-10 |
| WO2000028332A9 (en) | 2000-09-28 |
| IL143057A0 (en) | 2002-04-21 |
| MXPA01004683A (es) | 2002-09-18 |
| AU1911200A (en) | 2000-05-29 |
| DE69931279T2 (de) | 2007-04-12 |
| CA2350316A1 (en) | 2000-05-18 |
| WO2000028332A1 (en) | 2000-05-18 |
| JP2002529740A (ja) | 2002-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE326014T1 (de) | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma | |
| Roberts et al. | A cell-based model of thrombin generation | |
| Oka et al. | Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive | |
| Barrans et al. | Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases | |
| Kane et al. | Prebeta-1 HDL and coronary heart disease | |
| Marais et al. | Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E | |
| ZA200107598B (en) | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol. | |
| MY121405A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines | |
| MY130670A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | |
| MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
| Deakin et al. | HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity | |
| ATE204330T1 (de) | Verfahren zur bestimmung von cholesterin in high- density lipoproteinen | |
| ATE274068T1 (de) | Verfahren zur bestimmung von cholesterin in high- density-lipoprotein | |
| De Cristofaro et al. | The Asp272–Glu282 Region of Platelet Glycoprotein Ibα Interacts with the Heparin-binding Site of α-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III | |
| AU2864195A (en) | Class bi and ci scavenger receptors | |
| TW200510452A (en) | Compositions and methods for treating atherosclerosis | |
| WO2004005481A3 (en) | Methods for identifying modulators of mda-7 mediated apoptosis | |
| IL160533A0 (en) | Methods of screening molecules that are used to prevent cardiovascular diseases | |
| Daum et al. | Multiple dysfunctions of two apolipoprotein AI variants, apoA-I (R160L) Oslo and apoA-I (P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers | |
| Murthy et al. | Transglutaminase-catalyzed crosslinking of the Aα and γ constituent chains in fibrinogen | |
| Klein et al. | Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins | |
| Kinoshita et al. | Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL | |
| NO20002408L (no) | 5-HT1F antagonister | |
| DE69716057D1 (de) | Verfahren und zusammensetzungen zum nachweis von spleiss-mutationen in dihydropyremudine dehydrogenase | |
| Teusink et al. | Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |